Key Moments From UHG CEO's Testimony in the Senate

The latest stories trending on MedCity News.

Editor's Pick

Top Story Key Moments From the Change Healthcare Cyberattack Senate Hearing Andrew Witty, CEO of UnitedHealth Group, faced bipartisan outrage from senators on the Finance Committee angered by his company's cybersecurity failures. Here were the key moments from the hearing on Wednesday. Sponsored Content Get rewarded for your opinion! Complete our survey and receive an Amazon gift card! Presented by MedCity News As a health benefits expert, you have unique insights into how employers are adjusting to the evolving benefits landscape. We're looking to better understand the trends you're seeing among your clients, and we'd love to hear from you. Just complete our survey (which should take 10-15 minutes) and you'll receive a $20 Amazon gift card! INVEST 2024: Celebrating Growth in Women's Health Investments Join our INVEST 2024 panel to explore the transformative shift in women's health investments. Join Melissa Dennis (Partum Health), Melissa Lederer (mHUB & mHUB Ventures), Joe Connolly (Visana Health), and moderator Christiana DelloRusso (LRVHealth) to discuss this next phase in advancing women's health.   Register Now To Secure Your Spot

Featured News

Kaiser Permanente Is Deploying Innovaccer's Value-Based Care AI Across Washington Kaiser Permanente is deploying Innovaccer's healthcare AI platform and population health management tools to support better value-based care — starting with its Washington market and potentially expanding to new markets in the future. Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space. Pepper Bio's 'Google Maps for Drug Discovery' Finds Way to Potential New Liver Cancer Drug Pepper Bio has licensed rights to lerociclib, a molecule that G1 Therapeutics designed to offer dosing and safety advantages over approved therapies in the same drug class. EQRx previously held rights to the drug, but returned them after the company was acquired last year.

Resources

MedCity FemFwd: What Needs To Happen to Improve Preeclampsia Rates? In this episode, we're joined by John Auerbach, senior vice president of federal health at consulting firm ICF. He discusses rising preeclampsia rates and how stakeholders need to act. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe